Intrexon Corp (NASDAQ:XON) was the recipient of unusually large options trading on Tuesday. Stock investors acquired 2,424 put options on the stock. This represents an increase of 1,094% compared to the average volume of 203 put options.
Shares of NASDAQ:XON opened at $6.53 on Thursday. The company has a current ratio of 3.91, a quick ratio of 3.57 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $868.13 million, a P/E ratio of -4.77 and a beta of 1.84. Intrexon has a 52-week low of $3.95 and a 52-week high of $19.94.
Intrexon (NASDAQ:XON) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). The business had revenue of $23.30 million for the quarter, compared to analysts’ expectations of $32.12 million. Intrexon had a negative return on equity of 26.52% and a negative net margin of 363.14%. The business’s revenue for the quarter was down 41.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.36) EPS. As a group, equities research analysts predict that Intrexon will post -1.17 earnings per share for the current fiscal year.
Several brokerages recently issued reports on XON. Northland Securities cut Intrexon from an “outperform” rating to a “market perform” rating in a research note on Friday, March 1st. JMP Securities reissued a “buy” rating and issued a $43.00 price objective on shares of Intrexon in a research note on Wednesday, March 6th. Finally, BidaskClub raised Intrexon from a “sell” rating to a “hold” rating in a research note on Thursday, May 30th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $28.60.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Read More: Hedge Funds – How They Work For Investors
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.